<p>Evercore ISI 分析師 Gavin Clark-Gartner 維持了對 MIRM 股票的看漲態度，今天給予了買入評級。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
<p>Gavin Clark-Gartner 給予買入評級是基於與 Mirum Pharmaceuticals 戰略收購和市場潛力相關的多種因素。收購 Bluejay Tx 被視為一個非常有利的舉措，具有顯著的臨牀和監管成功潛力。該交易的結構具有較高的成功概率，預計的商業協同效應表明，Mirum Pharmaceuticals 只需實現適度的峯值銷售即可實現盈虧平衡。</p>
<p>此外，支持收購的臨牀數據非常強勁，具有合理的作用機制和良好的二期結果。即將進行的三期研究預計成功概率很高，特別是與現有治療方法相比。HDV 指標的市場規模相當可觀，Mirum Pharmaceuticals 預計在美國和國際市場上都將實現顯著的峯值銷售。這些因素為公司的股票前景提供了積極的展望，證明了買入評級和每股 94 美元的更新目標價的合理性。</p>
<p>根據 TipRanks，Clark-Gartner 是一位五星級分析師，平均回報率為 27.4%，成功率為 68.57%。Clark-Gartner 關注醫療保健行業，專注於 AbbVie、Vera Therapeutics 和 Insmed 等股票。</p>
<p>在今天發佈的另一份報告中，Cantor Fitzgerald 也維持了該股票的買入評級，目標價為 130.00 美元。</p>

MIRM

<p>Evercore ISI 分析師 Gavin Clark-Gartner 維持對 Mirum Pharmaceuticals 的 “買入” 評級，原因在於其戰略收購和市場潛力。收購 Bluejay Tx 是有利的，擁有強勁的臨牀數據和預期的商業協同效應。Mirum 預計 HDV 指標的峯值銷售額將顯著。Clark-Gartner 是一位五星級分析師，設定的目標價為每股 94 美元。Cantor Fitzgerald 也維持 “買入” 評級，目標價為 130 美元</p>

<p>Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on MIRM stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>Evercore ISI 分析師 Gavin Clark-Gartner 維持了對 MIRM 股票的看漲態度，今天給予了買入評級。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
</div><p>Gavin Clark-Gartner has given his Buy rating due to a combination of factors related to Mirum Pharmaceuticals’ strategic acquisition and promising market potential. The acquisition of Bluejay Tx is seen as a highly favorable move, with the potential for significant clinical and regulatory success. The deal is structured with a strong probability of success, and the expected commercial synergies suggest that Mirum Pharmaceuticals would only need to achieve a modest level of peak sales to break even.</p>
<div class="lb-trans"><p>Gavin Clark-Gartner 給予買入評級是基於與 Mirum Pharmaceuticals 戰略收購和市場潛力相關的多種因素。收購 Bluejay Tx 被視為一個非常有利的舉措，具有顯著的臨牀和監管成功潛力。該交易的結構具有較高的成功概率，預計的商業協同效應表明，Mirum Pharmaceuticals 只需實現適度的峯值銷售即可實現盈虧平衡。</p>
</div><p>Moreover, the clinical data supporting the acquisition is robust, with a logical mechanism of action and strong Phase 2 results. The upcoming Phase 3 studies are anticipated to have a high probability of success, particularly in comparison to existing treatments. The market size for the HDV indication is substantial, with Mirum Pharmaceuticals projecting significant peak sales both in the U.S. and internationally. These factors contribute to a positive outlook for the company’s stock, justifying the Buy rating and the updated price target of $94 per share.</p>
<div class="lb-trans"><p>此外，支持收購的臨牀數據非常強勁，具有合理的作用機制和良好的二期結果。即將進行的三期研究預計成功概率很高，特別是與現有治療方法相比。HDV 指標的市場規模相當可觀，Mirum Pharmaceuticals 預計在美國和國際市場上都將實現顯著的峯值銷售。這些因素為公司的股票前景提供了積極的展望，證明了買入評級和每股 94 美元的更新目標價的合理性。</p>
</div><p>According to TipRanks, Clark-Gartner is a 5-star analyst with an average return of 27.4% and a 68.57% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed.</p>
<div class="lb-trans"><p>根據 TipRanks，Clark-Gartner 是一位五星級分析師，平均回報率為 27.4%，成功率為 68.57%。Clark-Gartner 關注醫療保健行業，專注於 AbbVie、Vera Therapeutics 和 Insmed 等股票。</p>
</div><p>In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $130.00 price target.</p>
<div class="lb-trans"><p>在今天發佈的另一份報告中，Cantor Fitzgerald 也維持了該股票的買入評級，目標價為 130.00 美元。</p>
</div>

Strategic Acquisition and Market Potential Drive Buy Rating for Mirum Pharmaceuticals

- Evercore ISI 分析師 Gavin Clark-Gartner 維持對 MIRM 股票的買入評級。  
- 該評級基於 Mirum Pharmaceuticals 的戰略收購及市場潛力。  
- 收購 Bluejay Tx 被視為有利舉措，預計將帶來顯著的臨牀和監管成功。  

戰略性收購和市場潛力推動了對 Mirum Pharmaceuticals 的買入評級